Professor Tim Illidge is Professor of Targeted Therapy and Oncology at The Christie NHS Foundation Trust in Manchester. His clinical interest is lymphoma, while his research focuses on developing new antibody-based therapies and treatment approaches for lymphoma.

The Christie records that Professor Illidge completed medical and scientific training before undertaking research in lymphoma. He subsequently worked as a Senior Lecturer and Honorary Consultant in Oncology at Southampton University Hospitals NHS Trust from 1999 and moved his Cancer Research UK research group to Manchester and The Christie in 2004.

His work has therefore combined clinical oncology with laboratory and translational cancer research. Translational research aims to move scientific findings from laboratory studies toward clinical applications that may eventually benefit patients.

Professor Illidge has a particular research interest in antibody-based cancer therapies. Antibodies can be designed to recognise specific targets associated with cancer cells or the tumour environment. Some antibody therapies are now established components of cancer treatment, while other approaches remain under investigation.

He is also recognised for work involving radioimmunotherapy in lymphoma. This approach combines an antibody's ability to target particular cells with a radioactive component intended to deliver radiation to the target. The use of such therapies depends on the specific cancer, treatment history and clinical circumstances.

The Christie states that Professor Illidge has led numerous early- and late-phase clinical trials in lymphoma and has published extensively in the field. His research and clinical activities form part of the wider lymphoma programme at The Christie.

For patients researching lymphoma treatment in Manchester, his profile is relevant to targeted therapy, lymphoma, oncology research and clinical trials. Treatment decisions in lymphoma depend on the exact lymphoma subtype, disease extent, biological characteristics, previous treatment and patient-specific factors.

The Christie provides multidisciplinary cancer care, meaning that patients may be assessed by several specialists depending on their diagnosis. A lymphoma treatment plan may involve medical oncology, haematology, radiotherapy, imaging, pathology and specialist nursing services.

Patients from outside the United Kingdom should confirm referral and international-patient procedures directly with The Christie. Medical records such as pathology reports, scan results and previous treatment information may be required for specialist assessment.

Clinical trials can provide opportunities to investigate new cancer medicines and treatment approaches, but availability and eligibility vary. Patients should ask the clinical team about the purpose of a trial, possible benefits and risks, alternatives and the requirements for participation.

Professor Illidge also has academic and leadership responsibilities. The Christie identifies him as Deputy Director of the Institute of Cancer Sciences and Head of the Division of Cancer Sciences.

His profile is appropriate for a medical directory focusing on lymphoma, targeted cancer therapy, antibody-based treatment, radioimmunotherapy and cancer research.

For SEO purposes, useful terms include Professor Tim Illidge, The Christie Manchester, lymphoma specialist, targeted therapy oncology, lymphoma treatment, antibody therapy, radioimmunotherapy and cancer research UK.

Patients should use online information to understand a specialist's documented areas of work rather than as a substitute for personalised medical advice. The appropriate treatment depends on a complete clinical assessment.

Professor Tim Illidge's current consultant information and professional biography are available through The Christie NHS Foundation Trust, including his clinical specialty, research interests, academic qualifications and professional responsibilities.